^
    Back
    Association details:
    Biomarker:SRSF2 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:adavosertib (AZD1775) (WEE1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    ATR/CHK1/WEE1 Dependency in SRSF2-Mutated MDS/AML

    Published date:
    11/04/2021
    Excerpt:
    Analysis of ex vivo drug sensitivities in AML patient samples identified vulnerability to CHK1 and WEE1 inhibition in SRSF2-mutated AML: SRSF2 mutation is associated with sensitivity to the CHK1 inhibitors prexasertib (p = 0.006) (Fig 1 A and B) and PF-00477736 (p = 0.002) and the WEE1 inhibitor adavosertib (p = 0.003).
    DOI:
    10.1182/blood-2021-147960